Shanghai-headquartered private equity firm Yingke PE has led nearly 500 million yuan ($78 million) Series C round funding in Laviana Pharma Co., Ltd, a contract development manufacture organisation (CDMO) driven pharmaceutical firm.
The new round saw the participation of return investor HY Capital and new backers such as state-backed HRVC Capital and Space Holding Group, the investee announced on Wednesday.
The company will deploy the proceeds towards the construction of a manufacturing facility, research laboratory, and new drugs R&D.
Established in 2005, Laviana has set up three fully-owned subsidiaries in China and one overseas unit in the US.
Laviana had earlier completed three other rounds of financing from China Merchants Wealth Management, LYFE Capital, ABC Capital, Lotus Lake Capital, among others.
CHINA DEAL MONITOR
DealStreetAsia has also put together a table listing out all prominent venture capital transactions in the Greater China region on October 12 – 13, 2021.
